- Home
- AGIO vs CEPU Comparison
AGIO vs CEPU Comparison
Compare AGIO & CEPU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- CEPU
- Stock Information
- Founded
- AGIO 2007
- CEPU 1989
- Country
- AGIO United States
- CEPU Argentina
- Employees
- AGIO N/A
- CEPU N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- CEPU Electric Utilities: Central
- Sector
- AGIO Health Care
- CEPU Utilities
- Exchange
- AGIO Nasdaq
- CEPU Nasdaq
- Market Cap
- AGIO 1.4B
- CEPU 1.6B
- IPO Year
- AGIO 2013
- CEPU 2018
- Fundamental
- Price
- AGIO $32.09
- CEPU $13.03
- Analyst Decision
- AGIO Buy
- CEPU Hold
- Analyst Count
- AGIO 8
- CEPU 1
- Target Price
- AGIO $56.00
- CEPU $12.00
- AVG Volume (30 Days)
- AGIO 550.4K
- CEPU 366.8K
- Earning Date
- AGIO 05-01-2025
- CEPU 05-12-2025
- Dividend Yield
- AGIO N/A
- CEPU 2.38%
- EPS Growth
- AGIO N/A
- CEPU N/A
- EPS
- AGIO 11.45
- CEPU 0.06
- Revenue
- AGIO $37,035,000.00
- CEPU $697,204,690.00
- Revenue This Year
- AGIO $27.43
- CEPU $26.57
- Revenue Next Year
- AGIO $189.81
- CEPU N/A
- P/E Ratio
- AGIO $2.80
- CEPU $22.04
- Revenue Growth
- AGIO 25.96
- CEPU N/A
- 52 Week Low
- AGIO $23.42
- CEPU $7.07
- 52 Week High
- AGIO $62.58
- CEPU $16.60
- Technical
- Relative Strength Index (RSI)
- AGIO 65.51
- CEPU 56.54
- Support Level
- AGIO $29.05
- CEPU $13.07
- Resistance Level
- AGIO $30.45
- CEPU $13.65
- Average True Range (ATR)
- AGIO 1.13
- CEPU 0.69
- MACD
- AGIO 0.33
- CEPU 0.02
- Stochastic Oscillator
- AGIO 91.98
- CEPU 52.99
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a private-sector power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.